Bristol-Myers, Celgene link up for immuno-oncology combo trials
This article was originally published in Scrip
Executive Summary
Celgene has been bolstering Abraxane sales through added indications and now the big biotech is hoping to see a surge in the chemotherapy drug's revenues when it is paired with Bristol-Myers Squibb's highly anticipated immuno-oncology product nivolumab.